431
Views
11
CrossRef citations to date
0
Altmetric
Perspective

Do animal models hold value in Autism spectrum disorder (ASD) drug discovery?

, , &
Pages 727-734 | Received 06 Feb 2019, Accepted 16 May 2019, Published online: 27 May 2019

References

  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th Ed). Arlington (VA): American Psychiatric Pub Incorporated. 2013.
  • Chadman KK. Animal models for autism in 2017 and the consequential implications to drug discovery. Expert Opin Drug Discov. 2017;12(12):1–8.
  • Zhang X-C, Shu L-Q, Zhao X-S, et al. Autism spectrum disorders: autistic phenotypes and complicated mechanisms. World J Pediatr WJP. 2019;15(1):17–25.
  • Qin D, Wu S, Chen Y, et al. Behavioral screening tools for identifying autism in macaques: existing and promising tests. Brain Res Bull. 2018;146:87–93.
  • Meshalkina DA, Kizlyk MN, Kysil EV, et al. Zebrafish models of autism spectrum disorder. Exp Neurol. 2017;299(Pt A):207–216.
  • Hazell P. Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder. J Paediatr Child Health. 2007;43:19–24.
  • Siegel M, Beaulieu AA. Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice. J Autism Dev Disord. 2012;42:1592–1605.
  • Williams K, Brignell A, Randall M, et al. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2013;8:CD004677.
  • Roy A, Roy M, Deb S, et al. Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review. J Intellect Disabil Res JIDR. 2015;59:293–306.
  • Sandin S, Lichtenstein P, Kuja-Halkola R, et al. The heritability of autism spectrum disorder. Jama. 2017;318:1182–1184.
  • Wiśniowiecka-Kowalnik B, Nowakowska BA. Genetics and epigenetics of autism spectrum disorder-current evidence in the field. J Appl Genet. 2019;60(1):37–47.
  • Hui K, Katayama Y, Nakayama KI, et al. Characterizing vulnerable brain areas and circuits in mouse models of autism: towards understanding pathogenesis and new therapeutic approaches. Neurosci Biobehav Rev. In press.
  • Kas MJ, Glennon JC, Buitelaar J, et al. Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives. Psychopharmacology (Berl). 2014;231:1125–1146.
  • Kazdoba TM, Leach PT, Yang M, et al. Translational mouse models of autism: advancing toward pharmacological therapeutics. Curr Top Behav Neurosci. 2016;28:1–52.
  • Zhao H, Jiang Y-H, Zhang YQ. Modeling autism in non-human primates: opportunities and challenges. Autism Res Off J Int Soc Autism Res. 2018;11:686–694.
  • Servadio M, Vanderschuren LJMJ, Trezza V. Modeling autism-relevant behavioral phenotypes in rats and mice: do “autistic” rodents exist? Behav. Pharmacol. 2015;26:522–540.
  • Moy SS, Nadler JJ, Young NB, et al. Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains. Behav Brain Res. 2007;176:4–20.
  • Gumusoglu SB, Stevens HE. Maternal inflammation and neurodevelopmental programming: a review of preclinical outcomes and implications for translational psychiatry. Biol Psychiatry. 2019;85:107–121.
  • Deckmann I, Schwingel GB, Fontes-Dutra M, et al. Neuroimmune alterations in autism: a translational analysis focusing on the animal model of autism induced by prenatal exposure to valproic acid. Neuroimmunomodulation. 2018;25:285–299.
  • Malkova NV, Yu CZ, Hsiao EY, et al. Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav Immun. 2012;26:607–616.
  • Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? . Reprod Toxicol Elmsford N. 2009;28:1–10.
  • Nicolini C, Fahnestock M. The valproic acid-induced rodent model of autism. Exp Neurol. 2017;299(Pt A):217–227.
  • Frye RE. Social skills deficits in autism spectrum disorder: potential biological origins and progress in developing therapeutic agents. CNS Drugs. 2018;32:713–734.
  • Cook E, Leventhal B, Heller W, et al. Autistic children and their first-degree relatives: relationships between serotonin and norepinephrine levels and intelligence. J Neuropsychiatry Clin Neurosci. 1990;2:268–274.
  • Lake C, Ziegler MG, Murphy DL. Increased norepinephrine levels and decreased dopamine-β-hydroxylase activity in primary autism. Arch Gen Psychiatry. 1977;34:553–556.
  • Gillott A, Standen PJ. Levels of anxiety and sources of stress in adults with autism. J Intellect Disabil. 2007;11:359–370.
  • Tordjman S, McBride PA, Hertzig ME, et al. Plasma β-endorphin, adrenocorticotropin hormone, and cortisol in autism. J Child Psychol Psychiatr. 1997;38:705–715.
  • Ward MM, Mefford IN, Parker SD, et al. Epinephrine and norepinephrine responses in continuously collected human plasma to a series of stressors. Psychosom Med. 1983;45(6):471–486.
  • Gao B, Cutler M. Effects of acute and subchronic administration of propranolol on the social behaviour of mice; an ethopharmacological study. Neuropharmacology. 1992;31:749–756.
  • Sun H, Mao Y, Wang J, et al. Effects of beta-adrenergic antagonist, propranolol on spatial memory and exploratory behavior in mice. Neurosci Lett. 2011;498:133–137.
  • Villain H, Benkahoul A, Drougard A, et al. Effects of propranolol, a β-noradrenergic antagonist, on memory consolidation and reconsolidation in mice. Front Behav Neurosci. 2016;10:49.
  • Ratey JJ, Bemporad J, Sorgi P, et al. Brief report: open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. J Autism Dev Disorders. 1987;17:439–446.
  • Zamzow RM, Christ SE, Saklayen SS, et al. Effect of propranolol on facial scanning in autism spectrum disorder: A preliminary investigation. J Clin Exp Neuropsychol. 2014;36:431–445.
  • Zamzow RM, Ferguson BJ, Stichter JP, et al. Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study. Psychopharmacology (Berl). 2016;233:1171–1178.
  • Cataldo I, Azhari A, Esposito G. A review of oxytocin and arginine-vasopressin receptors and their modulation of autism spectrum disorder. Front Mol Neurosci. 2018;11:27.
  • Johnson ZV, Young LJ. Oxytocin and vasopressin neural networks: implications for social behavioral diversity and translational neuroscience. Neurosci Biobehav Rev. 2017;76:87–98.
  • Heinrichs M, von Dawans B, Domes G. Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol. 2009;30:548–557.
  • Modi ME, Young LJ. The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategies. Horm Behav. 2012;61:340–350.
  • Dai Y-C, Zhang H-F, Schön M, et al. Neonatal oxytocin treatment ameliorates autistic-like behaviors and oxytocin deficiency in valproic acid-induced rat model of autism. Front Cell Neurosci. 2018;12:355.
  • Hara Y, Ago Y, Higuchi M, et al. Oxytocin attenuates deficits in social interaction but not recognition memory in a prenatal valproic acid-induced mouse model of autism. Horm Behav. 2017;96:130–136.
  • Miller M, Bales KL, Taylor SL, et al. Oxytocin and vasopressin in children and adolescents with autism spectrum disorders: sex differences and associations with symptoms. Autism Res. 2013;6(2):91–102.
  • Huang H, Michetti C, Busnelli M, et al. Chronic and acute intranasal oxytocin produce divergent social effects in mice. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2014;39:1102–1114.
  • Bales KL, Solomon M, Jacob S, et al. Long-term exposure to intranasal oxytocin in a mouse autism model. Transl Psychiatry. 2014;4:e480.
  • Andari E, Duhamel J-R, Zalla T, et al. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci. 2010;107(9):4389–4394.
  • Keech B, Crowe S, Hocking DR. Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis. Psychoneuroendocrinology. 2018;87:9–19.
  • Chini B, Leonzino M, Braida D, et al. Learning about oxytocin: pharmacologic and behavioral issues. Biol Psychiatry. 2014;76:360–366.
  • Roberts BZ, Young JW, He YV, et al. Oxytocin improves probabilistic reversal learning but not effortful motivation in Brown Norway rats. Neuropharmacology. 2019;150:15–26.
  • Cho MM, DeVries AC, Williams JR, et al. The effects of oxytocin and vasopressin on partner preferences in male and female prairie voles (Microtus ochrogaster). Behav Neurosci. 1999;113:1071–1079.
  • Parker KJ, Garner JP, Oztan O, et al. Arginine vasopressin in cerebrospinal fluid is a marker of sociality in nonhuman primates. Sci Transl Med. 2018;10(439): eaam9100.
  • Veenema AH, Bredewold R, De Vries GJ. Vasopressin regulates social recognition in juvenile and adult rats of both sexes, but in sex- and age-specific ways. Horm Behav. 2012;61:50–56.
  • Ratni H, Rogers-Evans M, Bissantz C, et al. Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach. J Med Chem. 2015;58:2275–2289.
  • Umbricht D, Del Valle Rubido M, Hollander E, et al. A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2017;42:1924.
  • Bolognani F, Del Valle Rubido M, Squassante L, et al. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med. 2019.
  • Gogolla N, Leblanc JJ, Quast KB, et al. Common circuit defect of excitatory-inhibitory balance in mouse models of autism. J Neurodev Disord. 2009;1:172–181.
  • Stoppel LJ, Kazdoba TM, Schaffler MD, et al. R-baclofen reverses cognitive deficits and improves social interactions in two lines of 16p11.2 deletion mice. Neuropsychopharmacology. 2018;43:513–524.
  • Silverman JL, Pride MC, Hayes JE, et al. GABAB receptor agonist R-baclofen reverses social deficits and reduces repetitive behavior in two mouse models of autism. Neuropsychopharmacology. 2015;40:2228–2239.
  • Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012;4:152ra127.
  • Grandgeorge M, Lemonnier E, Degrez C, et al. The effect of bumetanide treatment on the sensory behaviours of a young girl with Asperger syndrome. BMJ Case Rep. 2014;2014:bcr2013202092.
  • Bruining H, Passtoors L, Goriounova N, et al. Paradoxical benzodiazepine response: a rationale for bumetanide in neurodevelopmental disorders? Pediatrics. 2015;136:e539–543.
  • Deidda G, Parrini M, Naskar S, et al. Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of down syndrome. Nat Med. 2015;21:318–326.
  • Krystal AD, Sutherland J, Hochman DW. Loop diuretics have anxiolytic effects in rat models of conditioned anxiety. Plos One. 2012;7:e35417.
  • Ko M-C, Lee M-C, Tang T-H, et al. Bumetanide blocks the acquisition of conditioned fear in adult rats. Br J Pharmacol. 2018;175:1580–1589.
  • Hadjikhani N, Zürcher NR, Rogier O, et al. Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study. Autism Int J Res Pract. 2015;19:149–157.
  • Hadjikhani N, Johnels JÅ, Lassalle A, et al. Bumetanide for autism: more eye contact, less amygdala activation. Sci Rep. 2018;8:3602.
  • Lemonnier E, Villeneuve N, Sonie S, et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry. 2017;7:e1056.
  • Su X, Jiang X, Meng L, et al. Anticancer activity of sulforaphane: the epigenetic mechanisms and the Nrf2 signaling pathway. Oxid Med Cell Longev. 2018;2018:5438179.
  • Bent S. Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli. Mol Autism. 2018;9(1):35.
  • Ferreira-Chamorro P, Redondo A, Riego G, et al. Sulforaphane Inhibited the nociceptive responses, anxiety- and depressive-like behaviors associated with neuropathic pain and improved the anti-allodynic effects of morphine in mice. Front Pharmacol. 2018;9:1332.
  • Zhang J-C, Yao W, Dong C, et al. Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation. J Nutr Biochem. 2017;39:134–144.
  • Gao J, Xiong B, Zhang B, et al. Sulforaphane alleviates lipopolysaccharide-induced spatial learning and memory dysfunction in mice: the role of BDNF-mTOR signaling pathway. Neuroscience. 2018;388:357–366.
  • Sunkaria A, Bhardwaj S, Yadav A, et al. Sulforaphane attenuates postnatal proteasome inhibition and improves spatial learning in adult mice. J Nutr Biochem. 2018;51:69–79.
  • Lynch R, Diggins EL, Connors SL, et al. Sulforaphane from broccoli reduces symptoms of autism: a follow-up case series from a randomized double-blind study. . Glob Adv Health Med. 2017;6:2164957X17735826–2164957X17735826.
  • Singh K, Connors SL, Macklin EA, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci U S A. 2014;111:15550–15555.
  • Jeon D, Kim S, Chetana M, et al. Observational fear learning involves affective pain system and Cav1.2 Ca2+ channels in ACC. Nat Neurosci. 2010;13:482–488.
  • Atsak P, Orre M, Bakker P, et al. Experience modulates vicarious freezing in rats: a model for empathy. PloS One. 2011;6:e21855.
  • Ben-Ami Bartal I, Rodgers DA, Bernardez Sarria MS, et al. Pro-social behavior in rats is modulated by social experience. eLife. 2014;3:e01385.
  • Ben-Ami Bartal I, Decety J, Mason P. Empathy and pro-social behavior in rats. Science. 2011;334:1427–1430.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.